Skip to content

A Randomized Controlled Trial of esketamine for fiberoptic bronchoscopy

Application of esketamine combined with propofol in bronchoscopy of children

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084991
Enrollment
Unknown
Registered
2024-05-29
Start date
2024-06-03
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric fiberbronchoscopy

Interventions

Propofol/fentanyl group :intravenous injection of propofol 2.0 mg/kg, fentanyl 1µg/kg
propofol/esketamine group:intravenous injection of propofol 2.0 mg/kg, esketamine 0.75 mg/kg

Sponsors

People's Hospital of Ningxia Hui Autonomous Region
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 12 Years

Inclusion criteria

Inclusion criteria: The children who were selected for fiberbronchoscopy under general anesthesia were 2-12 years old, ASA grade I to II, and weight was not limited.

Exclusion criteria

Exclusion criteria: Children with heart, liver and kidney function are obviously abnormal, coagulation function is abnormal, congenital heart disease, nervous system disease, mental disease, and allergic children to the study drugs.

Design outcomes

Primary

MeasureTime frame
Incidence of transient hypoxemia (SpO2 < 90%);

Secondary

MeasureTime frame
Systolic blood pressure, diastolic blood pressure, heart rate, respiratory rate, pulse oxygen saturation;Total dosage of propofol, time of first addition of propofol, satisfaction of bronchoscopy physicians;Success rate of one-time bronchoscope placement;The incidence of complications;

Countries

China

Contacts

Public ContactXiaomei Wang

People's Hospital of Ningxia Hui Autonomous Region

15825307684@163.com+86 158 2530 7684

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026